For context, heres how the most recent GLP-1 weight-loss drugs reached UK patients: Wegovy (semaglutide 2.4 mg): MHRA approval September 2021, NICE TA875 issued March 2023
Defendants engaged in this conduct even before GLP-1 RAs were approved for weight-loss, encouraging extensive off-label demand and use. Plaintiffs' co-lead counsel told Law360: "We are committed to achieving justice for the thousands of patients who suffered devastating injuries because these pharmaceutical giants recklessly put profits above patient safety." As the litigation surrounding GLP-1 receptor agonists continues to expand, significant updates have shaped the trajectory of the MDL
Novo Nordisk has also submitted an application for a dedicated 7.2 mg single-dose pen in the EU, which could become available later this year pending regulatory approval
Injections bypass the majority of this process and get right into your bloodstream, starting to work immediately
Moreover, consistent timing can help maintain stable medication levels in the bloodstream, which is often essential for long-term treatments like Tirzepatide
KPV plasma half-life: Approximately 10-15 minutes (small tripeptide)